echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Qilu's two Class 1 new drugs are coming raging and target the 100 billion market

    Qilu's two Class 1 new drugs are coming raging and target the 100 billion market

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Qilu Pharmaceutical has two Class 1 new drugs approved for clinical trials, namely the imported VB4-845 injection and the domestic Class 1 new drug QLS31901 for injection.


    Source: CDE official website

    The two innovative drugs approved by Qilu Pharmaceuticals recently are all anti-tumor drugs.


    VB4-845 injection is an antibody-drug conjugate (ADC) developed by Sesen Bio.


    At the end of July 2020, Qilu Pharmaceutical and Sesen Bio reached an exclusive licensing agreement to obtain the exclusive development and commercialization rights of the product in Greater China (Mainland China, Hong Kong, Macau and Taiwan) for a cooperative transaction amount of US$35 million.


    Since 2021, Qilu Pharmaceutical has applied for clinical or approved new drugs for marketing

    Source: Meinenet MED2.


    According to data from Meinenet, since 2021, Qilu Pharmaceutical has applied for clinical application of 3 new drugs of Class 1 and 2 of them have been approved for clinical use.


    Source: Minet database, CDE official website

    Note: The statistics are as of March 22.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.